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Abstract
During the past decade, the dual function of the immune system in tumor inhibition and tumor progression has
become appreciated. We have previously reported that neu-specific T cells can induce rejection of neu positive
mouse mammary carcinoma (MMC) and also facilitate tumor relapse by inducing neu antigen loss and epithelial to
mesenchymal transition (EMT). Here, we sought to determine the mechanism by which CD8+ T cells either eliminate
the tumor, or maintain tumor cells in a dormant state and eventually facilitate tumor relapse. We show that tumor
cells that express high levels of IFN-γ Rα are eliminated by CD8+ T cells. In contrast, tumor cells that express low
levels of IFN-γ Rα do not die but remain dormant and quiescent in the presence of IFN-γ producing CD8+ T cells until
they hide themselves from the adaptive immune system by losing the tumor antigen, neu. Relapsed tumor cells show
CD44+CD24- phenotype with higher rates of tumorigenesis, in vivo. Acquisition of CD44+CD24- phenotype in
relapsed tumors was not solely due to Darwinian selection. Our data suggest that tumor cells control the outcome of
tumor immune surveillance through modulation of the expression of    IFN-γ Rα.
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Introduction
Treatment of primary breast cancer frequently appears to be
initially successful; however, the disease may recur either
locally or as distant metastases years or even decades later,
where the tumor cells have been in a prolonged state of
dormancy. In fact, circulating tumor cells that are quiescent
have been detected in cancer free patients several years after
successful treatment, suggesting that tumor cells are in a state
of dynamic dormancy [1,2]. While the basis for tumor dormancy
and relapse is poorly understood, there is general agreement
that the immune response plays a critical role.
Tumor immunoediting has a dual function. On the one hand,
it inhibits tumor growth and results in the elimination of nascent
transformed cells; on the other hand, it edits the tumor resulting
in the escape and progression of less immunogenic tumor
cells. Bob Schreiber has formulated such opposing effects of
the immune system into three phases which include Elimination
or tumor rejection, Equilibrium or tumor dormancy, and Escape
or cancer formation (3Es) [3]. His group was first to show that
adaptive immune response can maintain the tumor in an
equilibrium phase or a dormant state, leading to tumor escape
[4]. Very recently, it was reported that the innate immune
system can also facilitate cancer immunoediting by the
production of IFN-γ [5]. These reports suggest a key role for
IFN-γ in linking the adaptive and innate immune system during
the process of tumor immunoediting.
We have previously shown that neu-specific IFN-γ producing
T cells concurrently induced tumor inhibition and tumor escape
that led to tumor relapse in FVB mice [6]. Subsequent analysis
revealed that such tumor immunoediting was associated with
epithelial to mesenchymal transition (EMT) and expression of
breast cancer stem cell markers in the relapsed tumor cells [7].
Here, we show that tumor immunoediting is facilitated through
IFN-γ/IFN-γ Rα axis such that low, but not high, levels of IFN-γ
Rα expression in tumor cells establish tumor equilibrium similar
to tumor dormancy, resulting in neu antigen loss and tumor
relapse in the presence of IFN-γ producing T cells.
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Results
Low expression of IFN-γ Rα in the tumor facilitates
tumor escape in the presence of neu-specific CD8+ T
cell response
We have previously reported a dual function of neu-specific
CD8+ T cell responses in facilitating tumor elimination or tumor
escape [6]. Here, we sought to determine whether such
opposing effects of CD8+ T cells are mediated through the IFN-
γ-IFN-γ Rα axis in vivo. To test this, we used FVB mice that
naturally mount neu-specific immune responses resulting in
complete rejection of neu positive mouse mammary carcinoma
(MMC) tumor cells within 3 weeks after challenge [6]. When
CD4+ and CD8+ T cells were depleted, FVB mice failed to
reject MMC [6]. In order to focus on CD8+ T cells and eliminate
the contribution of CD4+ T cells and antibody responses to the
tumor rejection, FVB mice were depleted of CD4+ T cells
during the course of study. Animals were then inoculated with:
i) wild type MMC tumor cell line that normally express low
levels of IFN-γ Rα (WT MMC); ii) wild type MMC with forced
expression of IFN-γ Rα (IFN-γ Rα++ MMC), or iii) wild type
MMC with the expression of dominant negative IFN-γ Rα
(dnIFN-γ Rα MMC). As shown in Figure 1A, presence of CD8+
T cells alone failed to reject WT MMC, though it resulted in the
cessation of tumor growth for over 2 months; animals
eventually succumbed to tumor relapse. All mice (4 mice/
group) rejected IFN-γ Rα++ MMC and dnIFN-γ Rα MMC tumor
cells. Rejection of dnIFN-γ Rα MMC tumor cells was consistent
with our previous observation showing that sorted IFN-γ Rα
negative MMC tumor cells were rejected by CD4-depleted FVB
mice [6]. We also performed in vivo tumor challenge studies in
the presence of GR20 antibody that blocks IFN-γ Rα, showing
that WT MMC tumor cells were rejected by CD4-depleted and
GR20-treated FVB mice (Figure S1). WT MMC and relapsed
MMC tumor cells were then analyzed for the expression of neu
and the stem cell markers CD44 and CD24. As shown in
Figure 1B, relapsed tumors lost neu expression as well as
CD24 expression. During equilibrium phase, tumor cells still
had neu expression and stem-like phenotype did not
remarkably change compared with WT MMC (data not shown).
Both WT MMC and relapsed ANV expressed low levels of IFN-
γ Rα (data not shown).
In order to determine if tumor escape or elimination was
mediated by neu-specific immune response, the three tumor
cell lines were inoculated into FVBN202 mice that tolerate neu
positive MMC. All tumor cell lines showed comparable rates of
growth in vivo within 4 weeks after challenge (p > 0.05), due to
the lack of an effective neu-specific T cell response (Figure
2A). All tumor cells also showed comparable rates of
proliferation in vitro, as determined by trypan blue exclusion
(Figure 2B).
IFN-γ induces apoptosis and inhibits tumor growth in
vitro
To determine whether IFN-γ may be responsible for tumor
escape and relapse of neu antigen negative variant (ANV) from
primary MMC tumors, WT MMC tumor cells, dnIFN-γ Rα MMC
or IFN-γ Rα++ MMC were cultured with IFN-γ (50 ng/106 cells/
ml). IFN-γ was added with fresh medium once every 3 days
and proliferation of adherent cells, i.e. viable cells was
determined while floater cells were excluded. As shown in
Figure 3A, IFN-γ induced apoptosis in the majority of WT MMC
cells within the first 6 days of culture (p < 0.02), thereafter
continuous supply of IFN-γ into the culture failed to induce
apoptosis such that all tumor cells remained viable. Compared
with control MMC tumor cells, IFN-γ treatment resulted in
significant inhibition, but not a complete cessation, of tumor cell
proliferation on days 3 (p=0.011), 6 (p=0.016), 10 (p=0.015)
(Figure 3B). Flow cytometry analysis showed downregulation of
the neu expression from an average MFI of 13.6 to 3.25 on
tumor cells within the first 14 days of culture with IFN-γ (Figure
3C). We have already shown that such downregulation of the
neu expression was associated with methylation of the neu
promoter [6]. IFN-γ also induced downregulation of CD24
Figure 1.  The neu-specific CD8+ T cells facilitate tumor
escape and relapse of WT MMC expressing low levels of
IFN-γ Rα.  WT MMC, IFN-γ Rα++ MMC and dnIFN-γ Rα MMC
cells were analyzed for IFN-γ Rα status by flow cytometry and
injected (5x106 cells) into CD4-depleted FVB mice (four mice
for each group) followed by monitoring tumor growth for 114
days (A). Also, evaluation of CD44+CD24- population and neu
expression in WT MMC at the time of tumor challenge (left
panel) and after tumor relapse (right panel) by flow cytometry
was done (B).
doi: 10.1371/journal.pone.0082544.g001
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expression such that CD44+CD24- stem-like MMC tumor cells
were increased from an average 10% to 55% (Figure 3D). The
removal of IFN-γ from the culture restored proliferation of tumor
cells as well as the expression of neu and CD24 within 2 weeks
(data not shown). As expected, the presence of IFN-γ did not
induce apoptosis in dnIFN-γ Rα MMC, though all IFN-γ Rα++
MMC cells died in the presence of IFN-γ (Figure 3E).
IFN-γ inhibits proliferation of CD44+CD24+ and
CD44+CD24- tumor cells
In order to determine if IFN-γ induces apoptosis in
CD44+CD24+ cells and select for CD44+CD24- cells within WT
MMC, we determined proliferation as well as apoptosis in each
subpopulation within WT MMC using multi-color flow cytometry
analysis. As shown in Figure 4A, IFN-γ treatment exhibited
comparable effects on the inhibition of cell proliferation. The
BrdU staining showed a 3-fold inhibition of cell proliferation in
CD24+ and CD24- cells after IFN-γ treatment. Also, Annexin
V/PI staining showed comparable decreases in the viability of
CD24+ and CD24- cells after a 3-day culture with IFN-γ (Figure
4A, 63% to 43% vs. 72% to 58%). Together, these data
suggest that the effect of IFN-γ on WT MMC is not simply
Darwinian selection of the CD44+CD24- subpopulation. To
further explore this, WT MMC were sorted into CD44+CD24+
and CD44+CD24- subpopulations in order to determine
whether CD44+CD24- subpopulation within MMC could expand
into a neu negative phenotype similar to ANV. As shown in
Figure 4B, both subpopulations expressed neu protein before
sorting. Sorted cells were then cultured in vitro in the absence
of IFN-γ for 2 months. Unlike ANV, CD44+CD24- MMC cells
retained the expression of neu throughout the in vitro culture;
they also retained CD44+CD24- phenotype with the expression
of the stem cell marker Sca1. Sorted CD44+CD24+ cells
established a cellular phenotype similar to WT MMC with 8%
CD44+CD24- cells.
MMC tumor cells contain CD44+CD24- stem-like cells
Since CD44+CD24- breast cancer cells have been
suggested to be cancer stem-like cells which also express the
stem cell marker Sca1, we sought to determine the stemness
capacity of the sorted cells. FVBN202 transgenic mice were
inoculated with a low dose of sorted CD44+CD24+ or
Figure 2.  In vivo and in vitro proliferation rate of WT MMC, IFN-γ Rα++ MMC and dnIFN-γ Rα MMC cells.  5x106 cells were
injected into FVBN202 mice (three repeats) and tumor growth as function of proliferation in vivo was monitored (A), also tumor cells
(0.25x 106/well in triplicates) were cultured for 3.5 days and were counted using trypan blue exclusion (B).
doi: 10.1371/journal.pone.0082544.g002
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CD44+CD24- MMC (50,000 cells/mouse). As shown in Figure
5A, sorted CD44+CD24+ cells failed to establish large tumors
within 3-4 weeks after challenge, whereas animals succumbed
to the tumor within 4 weeks after challenge with sorted
CD44+CD24- cells. No appreciable differences were observed
in the proliferation of sorted CD44+CD24+ and CD44+CD24-
MMC in vitro (Figure 5B). We also inoculated FVBN202 mice
with a low dose of relapsed ANV on the right side and with WT
MMC on the left side showing that ANV tumor cells were more
tumorigenic than WT MMC tumor cells (Figure S2).
Discussion
We have previously reported that neu tumor antigen loss
could occur in the presence of robust neu-specific immune
responses in FVB mice leading to tumor relapse of the neu
antigen negative variant, ANV [6]. We have also shown that
CD8+ T cells were involved in the epithelial to mesenchymal
transition (EMT) associated with neu antigen loss and tumor
relapse [7]. Here, we determined that neu-specific CD8+ T cells
induce tumor relapse through the IFN-γ-IFN-γ Rα axis. The
level of IFN-γ Rα expression on tumor cells was found to be a
key predictor of responsiveness of the tumor to CD8+ T cells.
High levels of IFN-γ Rα expression resulted in T cell-mediated
tumor rejection and relapse-free survival whereas low levels of
IFN-γ Rα expression facilitated CD8+ T cell-induced tumor
inhibition and retention of tumor equilibrium, leading to tumor
relapse. Rejection of dnIFN-γ Rα MMC by CD4-depleted FVB
mice was consistent with our previous observation showing
that sorted IFN-γ Rα negative MMC tumor cells were rejected
by CD4-depleted FVB mice [6]. This rejection could be due to
IFN-γ-independent mechanisms such as perforin/granzyme,
which is more active in the absence of IFN-γ signaling. We
observed that IFN-γ can induce expression of serine protease
inhibitor 6 (SPI6) in WT MMC whereas dnIFN-γ Rα MMC did
not express SPI6, thus remaining susceptible to granzyme B-
mediated apoptosis (unpublished data). SPI6 has been shown
to block granzyme-induced apoptosis [8,9], thereby inhibiting
IFN-γ-independent pathway of tumor rejection in tumor cells
that express low levels of IFN-γ Rα. Relapsed ANV tumor cells
showed characteristics of stem-like cells which included
CD44+CD24- phenotype, Sca1 expression, and high rates of
tumorigenicity in vivo. Finally, phenotype analysis by cell
sorting suggested that neu antigen loss and tumor relapse
were not merely due to Darwinian selection. These findings are
consistent with our previous reports on T cell-mediated
induction of EMT and IFN-γ-induced methylation of the neu
promoter [6,10].
Quiescent breast cancer cells have been detected in the
circulation of patients up to 22 years after diagnosis and
successful treatment [1]. These observations suggest that
tumor cells can remain in the state of dormancy, raising
concerns not only for breast cancer survivors but also for
cancer free individuals who may carry quiescent malignant
cells without clinical symptoms of cancer. Therefore,
understanding the mechanisms of tumor dormancy and
recurrence in immunocompetent individuals may lead to a
breakthrough in the treatment and elimination of breast cancer.
Figure 3.  Status of IFN-γ Rα expression in the tumor cells determines the type of response to IFN-γ.  WT MMC tumor cells
were cultured with IFN-γ (50 ng/ml/106 cells) for two weeks and were analyzed at different time points for viability (Annexin V-/PI-)
by flow cytometry (A), cell proliferation by trypan blue exclusion (B), neu expression (C) and evaluation of CD44+CD24- population
(D) by flow cytometry. E) dnIFN-γ Rα MMC or IFN-γ Rα++ MMC were also culture in the absence or presence of IFN-γ (50
ng/ml/106 cells) for 3 days and percent viable cells were counted by trypan blue exclusion. Data represent 2-3 independent
experiments.
doi: 10.1371/journal.pone.0082544.g003
The role of IFN-γ Rα in Tumor Immunoediting
PLOS ONE | www.plosone.org 4 December 2013 | Volume 8 | Issue 12 | e82544
Here, we showed that an effective CD8+ T cell response can
facilitate tumor equilibrium which may mimic tumor dormancy in
tumor clones that expressed low levels of IFN-γ Rα. Our finding
is consistent with previous reports in the murine B cell
lymphoma model, demonstrating that IFN-γ producing CD8+ T
cells, but not helper T cells, were required for the establishment
and maintenance of tumor dormancy in the immunized mice
[11]. Using a mouse model of primary chemical carcinogenesis,
Koebel et al. [4,12] also demonstrated that IFN-γ producing T
cells facilitate tumor dormancy by inhibiting proliferation of
tumor cells in vivo. They also showed that tumor cells in
dormant state or equilibrium are unedited but become edited
when they spontaneously escape immune control and grow
into clinically apparent tumors. IFN-γ was found to play a key
role in tumor escape by downregulating the expression of
NKG2D ligand on tumor cells [13,14], selecting for tumor
clones with reduced immunogenicity [15], and downregulating
the tumor antigen [6,16-19]. Very recently, DuPage et al. [17]
adapted a genetically engineered mouse model of sarcoma in
Figure 4.  The CD44+CD24- stem-like population and
CD44+CD24+ population of WT MMC respond similarly to
IFN-γ.  WT MMC tumor cells were cultured with or without IFN-
γ (50 ng/ml/106 cells) for 3 days and CD44+CD24- as
CD44+CD24- populations were analyzed for viability (Annexin
V-/PI-) and proliferation (BrdU) by flow cytometry (A), these two
population where sorted from WT MMC cells using a BD
FACSAria III cell sorter and cultured for 60 days, after that
analysis of CD24, CD44, Sca1 and neu was done (B) by flow
cytometry. Also analysis of relapsed ANV tumor is shown. Data
represent two independent experiments.
doi: 10.1371/journal.pone.0082544.g004
order to investigate the process of cancer immunoediting. They
found that primary sarcomas were immunoedited to become
less immunogenic and escape immune surveillance by losing
tumor antigen expression or presentation on MHC class I [17].
In patients with ductal carcinoma in situ (DCIS), HER-2/neu-
targeted vaccination induced HER-2/neu-specific IFN-γ
producing T cell responses and resulted in the inhibition of
DCIS as well as the induction of HER-2/neu antigen loss
[18,19]. In fact, IFN-γ producing T cells are involved in tumor
immune surveillance to inhibit primary tumors as well as in
tumor immunoediting to shape tumor dormancy, leading to
tumor escape by losing the target antigen in immunologically
intact individuals. We have previously reported variations in
tumor IFN-γ Rα expression in human breast tumor specimens
[20], suggesting a potential variation in the tumor
responsiveness to the immune system. It has been reported
that pro-inflammatory cytokines can modulate the expression of
IFN-γ Rα [21], again suggesting a link between inflammation
and tumor immune editing.
Dormant tumor cells are linked to the acquisition of cancer
stem-like characteristics. It has been well established that
breast cancer stem cells are characterized by CD44+CD24-
phenotype, expression of Sca1 with high rates of
tumorigenicity, in vivo [22-26]. Our data suggest that relapsed
tumor cells, ANV, show characteristics of breast cancer stem-
like cells. This is consistent with a recent report showing that
the CD44+CD24- phenotype contributes to breast cancer
relapse [23]. There was no correlation between stem-like cells
and levels of IFN-γ Rα expression, because ANV cells showed
low levels of IFN-γ Rα expression. Also, in WT MMC cells with
heterogeneity in the expression of IFN-γ Rα ranging from
negative to low expression, levels of IFN-γ Rα expression did
not correlate with stem-like cells (data not shown). However,
ANV cells were not able to generate CD44+CD24+ primary
MMC tumor cells, in vitro. In addition, phenotype analysis of
Figure 5.  CD44+CD24- stem-like tumor cells show greater
tumorigenicity compared with CD44+CD24+ population of
WT MMC.  WT MMC tumor cells were sorted into CD44+CD24-
and CD44+CD24- populations and on day twenty one, 50,000
of the sorted cells were injected into mice (n=2) and tumor
growth was observed. Sorted tumor cells were also cultured for
10 days (in triplicates) and counted using trypan blue
exclusion. Fold of expansions are shown (B).
doi: 10.1371/journal.pone.0082544.g005
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CD44+CD24+ and CD44+CD24- populations from within
primary MMC tumor cells suggest that relapsed ANV tumor
cells did not originate from the CD44+CD24- phenotype as a
result of immune selection; unlike ANV cells, the CD44+CD24-
phenotype of MMC retained neu expression during in vitro
culture. These findings are consistent with our previous
observation that neu antigen loss was due to epigenetic
modification resulting in the hypermethylation of the promoter
region of the neu gene [6]. Retention of CD44+CD24-
phenotype during in vitro and in vivo passages suggest that
CD44+CD24-Sca1+ cells may be a highly tumorigeneic
phenotype within the primary tumor cells which have
characteristics similar to stem-like cells, but they may not be
tumor initiating cells.
Here, we showed that tumor cells, but not the immune
response, can determine the outcome of anti-tumor adaptive
immune responses through modulation of the expression of
IFN-γ Rα. In a recent review article, we discussed both
preclinical and clinical evidence that highlight the opposing
function of IFN-γ producing T cells in tumor inhibition and tumor
escape or relapse [27]. Our data also suggest that CD8+ T
cells can facilitate tumor relapse through IFN-γ Rα which result
in the acquisition of stem-like phenotype. The genetic
complexity and heterogeneity of cancer is becoming
increasingly appreciated through genomic and histological
analyses. In fact, heterogeneity of breast cancer cells in the
levels of IFN-γ Rα expression suggests selective induction of
tumor dormancy only in the clones that express low levels of
IFN-γ Rα. Therefore, it would be critical to target these clones
in order to overcome tumor relapse.
Methods
Mice
Wild-type FVB (Jackson Laboratories) or FVBN202
transgenic (Charles River Laboratories) female mice (6–12
weeks of age) were housed under aseptic conditions and used
throughout these studies. The studies have been reviewed and
approved by the Institutional Animal Care and Use Committee
(IACUC) at Virginia Commonwealth University.
Depletion of lymphocytes
Depletion of CD4 was performed by i.p. injections of GK1.5,
as previously described by our group [7]. Briefly, animals were
injected with the GK1.5 (200–250 µg/mouse) on days -2 and -1
prior to tumor challenge followed by the injections once every 5
days until the completion of the trial. Depletion of the
lymphocyte subsets was assessed on the day of tumor
challenge and bi-weekly thereafter by FACS analysis of
peripheral blood. Blockade of IFN-γ Rα was performed by the
i.p. injection of GR20 antibody (200 µg/200 µl/mouse) prior to
tumor challenge and once every 3 days after tumor challenge.
Tumor cell lines
The neu overexpressing mouse mammary carcinoma (WT
MMC) cell line was established from the spontaneous
mammary tumors harvested from FVBN202 mice, as
previously described by our group [6]. The neu antigen-
negative variant (ANV) tumor cell line was derived from a
relapsed MMC tumor under the neu-specific immune pressure,
as previously described by our group [6]. The dnIFN-γ Rα and
IFN-γ Rα vectors were gifts from Dr. William Lee of the U Penn.
We established IFN-γ Rα++ MMC cell line by stable
transfection of pcDNA3 vector (Invitrogen) containing mouse
IFN-γ Rα ORF construct [7]. For this, cDNA of IFN-γ Rα was
amplified using mouse mammary tumor cDNA library as a
template in PCR reaction with proofreading polymerase
(Accuzyme, BioLine). PCR conditions were as follows: 94°C
3 min, 94°C 30 s, 48°C 30 s, 68°C 2 min (10 cycles); 94°C
30 s, 60°C 30 s, 68°C 2 min (20 cycles) followed by 10 min
extension at 68°C. Primers used in this reaction: sense: 5’-
TTTATGGTACCATGGGCCCGCAGGCGGCA-3’ and
antisense: 5’-TTAGATATCTTAGGACAGCTCCTGGGCCTC-3’
containing restriction sites for KpnI and EcoRV, respectively
(underlined). Amplified cDNA fragment and pcDNA3+ vector
(Invitrogen) were then digested with KpnI and EcoRV
endonucleases (NEB BioLabs) for preparing compatible ends
for ligation reaction. After ligation, constructs with insert were
isolated and sequenced to confirm intact expression of the
gene. Transfection of MMC cells with construct was done using
Lipofectamine 2000 Reagent (Invitrogen) according to
manufacture protocol. Tumor cells were maintained in RPMI
1640 supplemented with 10% FBS. We used G418 antibiotic at
a 200 µg/ml (Gibco) for the selection.
In vivo tumor challenge
Female mice were inoculated s.c. with the tumor cell lines as
previously described by our group [7]. Animals were inspected
twice every week for the development of tumors. Tumor
masses were measured using calipers along the two
perpendicular diameters. Tumor volume was calculated by: V
(volume) = L (length) x W (width)2 / 2. Mice were killed before a
tumor mass exceeded 2,000 mm3.
IFN-γ treatment
Adherent tumor cells were incubated with 50ng/ml of IFN-γ
(Biolegend) for 3 days. After a 3-day culture, cells were washed
and added with fresh medium containing IFN-γ every 5-7 days.
Flow cytometry
A three color staining flow cytometry analysis of the
mammary tumor cells (106 cells/tube) was carried out as
previously described by our group [7]. Fc blocking was
performed using anti-CD16/CD32 Ab (Biolegend). For Annexin
V staining, cells were stained for respective surface markers,
washed with cell staining buffer followed by washing with 1x
Annexin V buffer (BD Pharmingen). The Annexin V staining
protocol was then performed. We used following antibodies:
mouse anti-neu (Ab-4) (Calbiochem, San Diego, CA), isotype
control Ig, PE or FITC conjugated anti-mouse Ig (Biolegend),
FITC-conjugated Annexin V and propidium iodide (PI) (BD
Pharmingen, San Diego, CA), PE/Cy5-CD24, FITC-CD44, PE-
CD44, PE-Sca-1, PE-IFN-γ Rα and isotype Igs (Biolegend). All
Abs were used at the manufacture’s recommended
concentrations. Multicolor data acquisition was performed on a
The role of IFN-γ Rα in Tumor Immunoediting
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BD FACSCanto II and analyzed using BD FACSDiva software.
Cell cycle staining was done with standard protocol for staining
EtOH fixed cells with PI.
BrdU staining
FITC BrdU Flow Kit (BD Pharmingen) was used in
proliferation assays as described previously [21].
Cell sorting
To sort distinct cellular populations of WT MMC, 107 cells
were added to sample tubes in which FcRs were blocked and
surface markers were stained with PE-conjugated CD44 and
PE/Cy5-conjugated CD24 Abs. Cells were then washed with
sterile PBS supplemented with 2% FBS. The CD44+CD24+
and CD44+CD24- populations were sorted into 100% FBS
using a BD FACSAria III cell sorter.
Statistical analyses
Graphical data are presented as means with standard errors.
Statistical comparisons between groups were made using
Student’s t test with P< 0.05 being statistically significant.
Supporting Information
Figure S1.  Blockade of IFN-γ Rα in vivo result in CD8+ T
cell-mediated rejection of WT MMC. CD4-depleted FVB mice
(n=2) were injected i.p. with GR20 antibody and then
inoculated with WT MMC tumor cells (3x106 cell/mouse).
Animals received GR20 antibody once every three days and
tumor growth was determined.
(PDF)
Figure S2.  ANV tumor cells are more tumorigenic than WT
MMC tumor cells. FVBN202 mice (n=4) were inoculated with a
low dose (60,000/mouse) ANV tumor cells on the right side and
WT MMC tumor cells on the left side. Tumor growth was
monitored.
(PDF)
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